Dementia Action Week 2024
Dementia Action Week 2024
Dementia Action Week 2024 (13th ā 20th May)
The term Dementia describes the different brain disorders that trigger a loss of brain function. These conditions are all usually progressive and eventually severe. Alzheimerās Disease is the most common type of dementia, affecting 62 per cent of all those diagnosed.
Dementia is a general term for loss of memory, language, problem-solving and other thinking abilities that are severe enough to interfere with daily life.Ā Common symptoms include memory loss, confusion, and speech problems. Early warning signs may also include finding it difficult to follow conversations, or programs on TV, forgetting names of friends, or everyday objects and feeling confused even in a familiar environment.
Mainly affecting older people, after the age of 65, the likelihood of developing dementia roughly doubles every five years ā however, for some dementia can develop earlier, presenting different issues for the person affected, their carer and their family. There is also a considerable economic cost associated with the disease estimated at Ā£23 billion a year, which is predicted to triple by 2040. This is more than the cost of cancer, heart disease, and stroke.
At Randox, we recognise the importance in diagnosing dementia early. Ā Through our Randox Ā Alzheimer’s Disease Array which can be used for Rapid Identification of Alzheimerās Disease Risk. Randoxās Alzheimerās Disease Risk Array can be used for the direct determination of ApoE4 status from plasma, eliminating the need for genetic testing, assisting in clinical research and personalised medicine strategies. At Randox, we believe the importance of measuring ApoE4 protein expression in plasma is the way forward to screen those individuals at increased risk of Alzheimer Disease, as new beta amyloid-targeting therapies for this condition are being expected.
Race Against Dementia have been the partner charity for the Randox Grand National Festival over the past two years, working alongside this charity which was founded by three-times Formula One World Champion, Sir Jackie Stewart, with the aim of funding much needed pioneering research into the prevention and cure of dementia.
For further information about the Randox Alzheimerās Array please emailĀ info@randoxbiosciences.com
Focus on Chronic Kidney Disease diagnosis (CKD)
Chronic Kidney Disease (CKD) is a long term condition which involves the progressive loss of kidney function a late diagnosis can result in end stage renal disease requiring kidney dialysis or transplantation. Typically, CKD is result of a combination of other conditions which puts a strain on the kidneys, these conditions can include high blood pressure, diabetes and high cholesterol amongst many other ailments.1
Randox Biosciences are continually researching and developing new tests, targeting various health concerns around the world to improve diagnostics and health worldwide. Recently, our dedicated scientists have developed a new test, utilising our proprietary Biochip Array Technology (BAT) that simultaneously and quantitatively detects multiple early biomarkers associated with kidney damage allowing for earlier intervention and treatment, preventing further kidney damage.
We offer two multiplex Chronic Kidney Arrays as shown below:
Early detection provides those diagnosed with the opportunity to alter their lifestyle in order to improve their kidney and overall health, whether that is through the reduction of salt in their diet, increased physical activity and alcohol limitation.
To find out more about the Chronic Kidney Disease Arrays offered by Biosciences email info@randoxbisociences.com
1 NHS – https://www.nhs.uk/conditions/kidney-disease/
Randox and Chan Zuckerberg Initiative share common goal
You may have read in the news this week that the Chan Zuckerberg Initiative co-founded by Mark Zuckerberg has pledged to invest $3 billion over the next decade to help further and advance medical research. Investments will go towards a research facility, named the Biohub, which will focus on developing new tools to research, understand and treat diseases, and of particular interest to us here at Randox, on creating a chip to diagnose disease.
Here at Randox we fully support this drive to further research that is devoted to revolutionising healthcare. We commit up to 16% of turnover to research and development each year and currently over 20% of the world’s major laboratories are using Randox products.
In particular, we invested £220 million into the development of our Biochip Array Technology (BAT). The Randox biochip has revolutionised the diagnostics industry by facilitating the detection of a wide range of markers of disease from a single undivided sample. This not only enhances patient diagnosis but reduces the amount of time spent on individual tests and associated laboratory costs.
Our expertise, highly specialised scientists and world-class ISO accredited manufacturing facilities enables early, accurate, informed clinical decisions in the areas of veterinary testing, molecular research and diagnostics, drug development, food safety and forensic and clinical toxicology.
Our Randox Health clinics use our Biochip to allow people to avail of the complete portfolio of Randox routine and novel tests to empower their health decisions. This new and exciting service provides personalised and preventive health profiling for each individual.
Speaking about the biochip Dr. Peter FitzGerald, Founder and Managing Director of Randox said,
“Many years of development and the expertise of our highly qualified scientists have gone into the creation of Randox Biochip Array Technology. This scientific development will facilitate the simultaneous quantitative or qualitative detection of a wide range of analytes from a single undivided sample. This approach both proteomic and genomic enables an enhanced patient diagnosis, optimum efficiency and consolidation of cost. Our arrays are suitable for use in a wide range of settings including clinical and research laboratories, biopharmaceutical organisations, forensic and clinical toxicology, hospital laboratories, food testing and veterinary laboratories.”
We are delighted that Chan Zuckerberg’s interest in this area brings to the forefront the importance of improving healthcare through innovative diagnostics. It is clear that Randox and the Chan Zuckerberg Initiative share a common goal to revolutionise healthcare worldwide and we believe that the Randox Biochip can play an important role in realising this vision.
For further information please contact our Randox Comms Team on 028 9445 1016 or email amy.mcilwaine@randox.com
